Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer

M. F. Sarosdy, Ralph W deVere White, M. S. Soloway, J. Sheinfeld, M. A. Hudson, P. F. Schellhammer, M. V. Jarowenko, G. Adams, B. A. Blumenstein

Research output: Contribution to journalArticlepeer-review

191 Scopus citations

Abstract

Objectives: We compare the Bard BTA † Bainbridge Diagnotic Sciences, C.R. Bard, Inc., Redmond, WA. (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer. Materials and Methods: A prospective, blinded, multicenter trial was performed. Results: A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was mode sensitive than cytology studies in detecting recurrent cancer (p less than 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9 percent. Conclusions: The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalThe Journal of Urology
Volume154
Issue number2
DOIs
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer'. Together they form a unique fingerprint.

Cite this